World’s largest drugmaker to buy its rival for $68 billion
A merger of Pfizer and Wyeth could trigger a wave of consolidation in the cash-rich pharmaceutical sector as drug makers look to diversify revenues in the face of competition from generic-drug rivals, analysts said. “Consolidation is a necessary evil in Big Pharma. This sector must consolidate now and Pfizer is the poster child.”
